Leerink cuts CVS Health target to USD 112: CVS Health stock gains 1.47 percent

Published on 10/15/2026 at 10:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock costs EUR 81.93 on October 15, 2026, 1.47 percent above the Xetra close. Q2 revenue reached USD 106.10 billion.

Leerink revises its valuation view

Leerink Partners cut its CVS Health target from USD 119.00 to USD 112.00 on October 12, 2026.
Second-quarter revenue reached USD 106.10 billion on August 5, 2026, up 7.30 percent year over year.
CVS Health stock trades at EUR 81.93 at 10:47 a.m. CEST at Lang & Schwarz on October 15, 2026, 1.47 percent above the Xetra close of October 14, 2026.

Extreme Nahaufnahme bunter pharmazeutischer Kapseln und Tabletten mit Bokeh-Hintergrund — CVS Health Corp. Makroaufnahme zeigt bunte Pharmakapseln und Tabletten in Detailansicht, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (ISIN US1266501006) was trading at EUR 81.93 at Lang & Schwarz on October 15, 2026, at 10:47 a.m. CEST, up 1.47 percent versus the Xetra close of October 14, 2026 at EUR 80.74. The move follows a valuation reset by Leerink Partners, which cut its CVS Health price target from USD 119.00 to USD 112.00 on October 12, 2026, while maintaining an Outperform rating, according to Markets Insider.

Target cut sharpens valuation

Leerink's new target remains above the latest US market quote, but the direction of the revision points to more cautious assumptions before third-quarter results. MarketBeat reported that 20 analysts carried Buy ratings and three carried Hold ratings, with a consensus target of USD 107.80. The same report cited a fiscal 2026 adjusted earnings-per-share outlook of USD 7.90 to USD 8.10.

Three steps shaped the story

On May 6, 2026, CVS Health reported first-quarter revenue of USD 100.43 billion, according to the company's filing summary carried by TickerScout. On August 5, 2026, second-quarter revenue rose to USD 106.10 billion, up 7.30 percent year over year, while adjusted earnings per share reached USD 2.58, according to MarketBeat. On October 12, 2026, Leerink lowered its target from USD 119.00 to USD 112.00.

What does the target cut mean?

The central test is whether CVS can convert its strong second-quarter revenue base into steadier insurance profitability. The company operates health benefits, pharmacy services, retail pharmacies and prescription drug coverage, giving the group multiple earnings channels but also exposing it to medical-cost and regulatory pressure. CVS Health's most recent official company description cited approximately 9,000 retail pharmacies, more than 1,000 clinics, 87 million pharmacy-benefit members and 37 million people served through health insurance products as of June 30, 2026.

Two dates set the next checkpoints

CVS Health declared a quarterly dividend of USD 0.665 per share on September 30, 2026, payable on November 2, 2026, to shareholders of record on October 22, 2026, according to CVS Health. The company scheduled its third-quarter 2026 results conference call for November 4, 2026, at 8:00 a.m. ET, according to CVS Health.

Stock advances before the next report

The euro quote is above the Xetra close while the analyst revision keeps valuation and insurance cost trends central to the next earnings review. CVS Health was trading at EUR 81.93 at Lang & Schwarz on October 15, 2026, at 10:47 a.m. CEST, 1.47 percent above the Xetra close of October 14, 2026 at EUR 80.74. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.